← All indications
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Subtype terms (3)
More specific conditions that are subtypes of Cystitis in the MeSH hierarchy.
- Cystitis, Hemorrhagic
- Cystitis, Interstitial
71 drugs (42 approved, 29 experimental)
- Pyelocystitis
Drugs by status
Approved for this indication (10)
Phase 4 trials (14)
Phase 3 trials (7)
Phase 2 trials (4)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (23)
- Allergan
- Citrus Valley Medical Research, Inc.
- Fundação Educacional Serra dos Órgãos
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Harvard University
- University of Washington
- Mansoura University
- Northwestern University
- University of Iowa
- University of Rochester
- Wake Forest University
- University of Calgary
- University of Chicago
- Icahn School of Medicine at Mount Sinai
- Emek Medical Center
- Technion University
- University of Genoa
- University of Alabama, Birmingham
- European Commission
- Paul G. Allen Family Foundation
- University of Geneva
- Laboratório Gross S.A.
Organization Involved with Phase 3 Indications (16)
- Abbott
- Astellas
- Eurofarma Laboratorios S.A.
- ICStudy, LLC
- Tedec-Meiji Farma, S.A.
- University of Pennsylvania
- Henry Ford Health System
- Hoosier Cancer Research Network
- Philadelphia Urosurgical Associates
- University of Louisville
- University of Pavia
- Yale University
- Hofstra University
- Aquinox Pharamceuticals Inc
- University of Gothenburg
- AlloVir
Organization Involved with Phase 2 Indications (29)
- MediciNova
- Novo Nordisk
- Pfizer
- GlaxoSmithKline
- Lipella Pharmaceuticals, Inc.
- Mundipharma
- Paratek Pharmaceuticals Inc
- Seikagaku Corporation
- Teva
- Urigen
- United States Army
- University of Pittsburgh
- Baylor University
- Tzu Chi University
- Duke University
- Min-Sheng General Hospital
- Oakland University
- Queen's University, Belfast
- Stanford University
- University of California, San Diego
- Karolinska Institute
- Watson Pharmaceuticals
- University of Texas at Houston
- Scripps
- Department of Health and Human Services
- Government of Canada
- TARIS Biomedical, Inc.
- Acrobio Healthcare Inc.
- Study Group for Urogenital Diseases, Italy
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (12)